Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Hongbo Lu Sells 2,970 Shares of Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Hongbo Lu sold 2,970 shares of the firm’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total transaction of $228,333.60. Following the completion of the transaction, the director directly owned 52,012 shares of the company’s stock, valued at approximately $3,998,682.56. The trade was a 5.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR opened at $79.69 on Friday. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $14.30 and a 52-week high of $82.26. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23. The company has a market capitalization of $11.23 billion, a P/E ratio of -37.06 and a beta of 1.28. The company has a fifty day moving average of $65.71 and a 200-day moving average of $61.75.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The company had revenue of $73.74 million during the quarter, compared to the consensus estimate of $73.84 million. During the same period in the previous year, the firm posted $2.75 EPS. The firm’s revenue was down 86.4% compared to the same quarter last year. As a group, equities research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.97 EPS for the current fiscal year.

Institutional Trading of Arrowhead Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Arrowhead Pharmaceuticals by 3.3% in the third quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company’s stock worth $553,077,000 after purchasing an additional 510,798 shares during the last quarter. Avoro Capital Advisors LLC increased its position in shares of Arrowhead Pharmaceuticals by 2.8% in the third quarter. Avoro Capital Advisors LLC now owns 10,900,000 shares of the biotechnology company’s stock valued at $375,941,000 after acquiring an additional 300,000 shares during the period. Geode Capital Management LLC increased its position in shares of Arrowhead Pharmaceuticals by 4.3% in the fourth quarter. Geode Capital Management LLC now owns 3,264,963 shares of the biotechnology company’s stock valued at $216,799,000 after acquiring an additional 133,921 shares during the period. Baker BROS. Advisors LP increased its position in shares of Arrowhead Pharmaceuticals by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 2,175,645 shares of the biotechnology company’s stock valued at $144,441,000 after acquiring an additional 504,883 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of Arrowhead Pharmaceuticals by 0.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,087,953 shares of the biotechnology company’s stock valued at $138,619,000 after acquiring an additional 6,264 shares during the period. 62.61% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, May 6th. Sanford C. Bernstein increased their target price on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a report on Wednesday. B. Riley Financial boosted their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. JPMorgan Chase & Co. initiated coverage on shares of Arrowhead Pharmaceuticals in a research note on Friday, May 1st. They issued an “overweight” rating and a $88.00 price target for the company. Finally, Royal Bank Of Canada boosted their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $87.80.

More Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Arrowhead announced a global license and collaboration agreement with Sarepta Therapeutics for multiple clinical and preclinical programs, a potentially meaningful pipeline expansion that could improve future commercialization prospects. Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs
• Positive Sentiment: HC Wainwright maintained a Buy rating and $100 price target while lifting some longer-term earnings estimates, reinforcing a bullish stance on Arrowhead’s future growth.
• Positive Sentiment: Sanford C. Bernstein raised its price target on Arrowhead from $35 to $46, signaling improved confidence even though its rating remains only market perform.
• Neutral Sentiment: Arrowhead presented at the Bank of America Global Healthcare Conference, but no major new clinical or financial update was included in the transcript headline. Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: HC Wainwright made only small mixed changes to its earnings forecasts for 2026-2027, which may affect sentiment but do not materially alter the overall bullish thesis.
• Neutral Sentiment: Director Hongbo Lu sold 2,970 shares in a pre-arranged 10b5-1 transaction; because it was planned and relatively small versus his holdings, it is not a strong negative signal on its own.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.